MedTrace Logo

The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

NCT03144596 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2017-05-09

No results posted yet for this study

Summary

It was aimed to evaluate and investigate the effects of tamsulosin hydrochloride, has preferential selectivity for the α1A receptor in the prostat versus the α1B receptor in the blood vessels, and alfuzosin hydrochloride on choroidal thickness (CT), pupil diameter sizes evaluated by using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT) and scheimpflug/placido photography-based topoghraphy system in this study.

63 men patients with newly diagnosis of benign prostatic hyperplasia were randomly assigned to either alfuzosin hydrochloride or to tamsulosin hydrochloride groups in this prospective, randomized, parallel-group clinical trial. Enhanced depth imaging spectral-domain optical coherence tomography, pupillography were obtained at baseline, 1st and 3rd month, and choroidal thicknesses and pupil diameter sizes were compared between the 2 groups.

Conditions

  • Benign Prostatic Hyperplasia
  • Pupil Anomaly
  • Choroid Disease

Interventions

DRUG

Alfuzosin Hydrochloride 10 MG

Alfuzosin hydrochloride Tablet

DRUG

Tamsulosin Hydrochloride 0.4 MG

Tamsulosin Hydrochloride Tablet

Sponsors & Collaborators

  • Kocatepe University

    lead OTHER

Principal Investigators

  • Mustafa Dogan, Asst. Prof. · Afyon Kocatepe University Eye Clinics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-29
Primary Completion
2016-02-03
Completion
2016-11-19
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03144596 on ClinicalTrials.gov